Recent Advances in Ablative Therapies for HCC
- PMID: 40535845
- PMCID: PMC12173004
- DOI: 10.1016/j.jceh.2025.102592
Recent Advances in Ablative Therapies for HCC
Abstract
Hepatocellular carcinoma (HCC) is the sixth most common cause of cancer worldwide and ranks third in terms of cancer related mortality. The management options for earlystage HCC include surgical resection, liver transplantation and percutaneous imageguided ablation. However, majority of the patients are not appropriate candidates for liver transplantation or surgical resection. Thus, image-guided tumour ablation has evolved as an accepted curative management option for these patients, according to most of the HCC management guidelines, due to its less invasive nature and proven efficacy. The aim of this article is to review the currently available data and the latest techniques for percutaneous ablation of HCC.
Keywords: Irreversible electroporation therapy; ablation techniques; carcinoma hepatocellular; cryosurgery; radiofrequency ablation.
© 2025 Indian National Association for Study of the Liver. Published by Elsevier B.V.
Conflict of interest statement
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
References
-
- Bray F., Laversanne M., Sung H., et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229–263. - PubMed
-
- de Martel C., Georges D., Bray F., Ferlay J., Clifford G.M. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Global Health. 2020 Feb;8:e180–e190. - PubMed
-
- Child C.G., Turcotte J.G. Surgery and portal hypertension. Major Probl Clin Surg. 1964;1:1–85. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
